Ascentage Pharma Group International (AAPG)

$0.00

$0 (0%)
Last update: 07:00 PM EST
Day's range
$21.99
Day's range
$23.69

AAPG Income statement / Annual

Last year (2025), Ascentage Pharma Group International's total revenue was $558.48 M, a decrease of 43.05% from the previous year. In 2025, Ascentage Pharma Group International's net income was -$1.21 B. See Ascentage Pharma Group International,s key income statements, including revenue, expenses, profit, and income.

Period FY-2025 FY-2024 FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016
Period Ended 12/31/2025 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Operating Revenue $558.48 M $980.65 M $221.98 M $209.71 M $27.91 M $12.45 M $14.51 M $6.81 M $6.33 M $7.67 M
Cost of Revenue $131.73 M $29.09 M $30.54 M $22.00 M $3.33 M $1.97 M $2.10 M $0.00 $0.00 $261.00 K
Gross Profit $426.75 M $951.57 M $191.44 M $187.71 M $24.58 M $10.48 M $12.42 M $6.81 M $6.33 M $7.41 M
Gross Profit Ratio 0.76 0.97 0.86 0.9 0.88 0.84 0.86 1 1 0.97
Research and Development Expenses $1.08 B $947.25 M $706.97 M $743.10 M $766.49 M $564.57 M $463.88 M $249.57 M $118.82 M $102.69 M
General & Administrative Expenses $0.00 $187.13 M $181.08 M $170.60 M $143.51 M $62.69 M $98.85 M $89.22 M $13.41 M $17.71 M
Selling & Marketing Expenses $0.00 $196.00 M $195.39 M $157.42 M $47.75 M $1.37 M $0.00 $496.00 K $0.00 $0.00
Selling, General & Administrative Expenses $522.67 M $383.12 M $376.46 M $328.02 M $191.26 M $64.06 M $98.85 M $89.72 M $13.41 M $17.71 M
Other Expenses $6.99 -$9.07 M -$19.36 M -$33.60 M -$63.34 M $45.80 M $32.37 M -$8.63 M $4.78 M $1.63 M
Operating Expenses $1.61 B $1.32 B $1.06 B $1.04 B $894.42 M $674.43 M $595.10 M $330.65 M $137.00 M $122.03 M
Cost And Expenses $1.74 B $1.35 B $1.09 B $1.06 B $961.08 M $676.39 M $597.20 M $330.65 M $137.00 M $122.29 M
Interest Income $79.89 M $37.84 M $32.41 M $9.73 M $7.11 M $5.22 M $12.91 M $7.06 M $304.00 K $13.00 K
Interest Expense $52.60 M $64.46 M $96.06 M $52.79 M $16.73 M $6.26 M $4.27 M $36.92 M $57.94 M $3.26 M
Depreciation & Amortization $84.12 M $93.17 M $93.20 M $47.42 M $17.18 M $16.97 M $3.83 M $18.46 M $12.50 M $164.37 K
EBITDA -$1.10 B -$237.63 M -$743.61 M -$786.97 M -$798.34 M -$652.23 M -$1.47 B -$291.53 M -$49.68 M -$103.03 M
EBITDA Ratio -1.96 -0.24 -3.35 -3.75 -28.6 -52.39 -101.58 -42.83 -7.85 -13.44
Operating Income Ratio -2.11 -0.38 -3.93 -4.05 -31.17 -53.33 -40.15 -7.38 -20.65 -14.95
Total Other Income/Expenses Net -$23.21 M -$25.53 M -$60.23 M -$37.36 M $37.59 M -$11.51 M -$899.63 M -$23.07 M $10.55 M $6.78 M
Income Before Tax -$1.20 B -$395.26 M -$932.86 M -$887.17 M -$832.25 M -$675.45 M -$1.48 B -$346.91 M -$120.12 M -$107.84 M
Income Before Tax Ratio -2.15 -0.4 -4.2 -4.23 -29.82 -54.25 -102.14 -50.96 -18.98 -14.07
Income Tax Expense $6.75 M $10.43 M -$7.15 M -$4.25 M -$49.83 M $2.16 M -$1.60 M -$1.60 M -$1.60 M $0.00
Net Income -$1.21 B -$405.43 M -$925.64 M -$882.92 M -$782.42 M -$677.61 M -$1.48 B -$345.31 M -$118.51 M -$107.84 M
Net Income Ratio -2.16 -0.41 -4.17 -4.21 -28.03 -54.43 -102.03 -50.73 -18.73 -14.07
EPS -13.56 -5.36 -52.48 -53.6 -49.12 -50.24 -112.04 -26.68 -9.16 -8.32
EPS Diluted -13.56 -5.36 -52.48 -53.6 -49.12 -50.24 -112.04 -26.68 -9.16 -8.32
Weighted Average Shares Out $89.03 M $75.52 M $17.64 M $16.48 M $15.91 M $13.49 M $13.22 M $12.94 M $12.94 M $12.94 M
Weighted Average Shares Out Diluted $89.03 M $75.52 M $17.64 M $16.48 M $15.91 M $13.49 M $13.22 M $12.94 M $12.94 M $12.94 M
Link